Skip to main content

Table 3 Soluble markers

From: No evidence of a synergistic effect of HIV infection and diabetes mellitus type 2 on fat distribution, plasma adiponectin or inflammatory markers

  HIV + DM2+ HIV + DM2- Controls with DM2 Healthy controls P
Adiponectin (μg/mL) 9.79 (8.02–11.56) 13.83 (10.07–17.06)* 8.63 (6.96–10.29) 14.96 (12.80–17.11)* < 0.001
IL-6 (pg/mL) 2.16 (1.16–3.15) 1.04 (0.67–1.41)* 3.89 (0.89–8.66) 0.91 (0.72–1.11)* 0.050
TNF-alfa (pg/mL) 3.24 (2.66–3.82) 2.92 (2.01–3.84) 4.02 (1.32–6.73) 2.29 (2.07–2.51) 0.112
sCD14 (ng/mL) 2333 (1935–2732) 2218 (1912–2525) 1461 (1277–1644)* 1504 (1302–1706)* < 0.001
  1. Soluble markers presented as mean (95%CI) before log transformation. P-value represent one-way ANOVA analyses after log transformation followed by t-test for comparison between HIV + DM2+ and the 3 control groups when ANOVA test was *p < 0.05 compared to HIV+DM2+
  2. Abbreviations: HIV + DM2+ People living with HIV with diabetes mellitus type 2, HIV + DM2- People living with HIV without diabetes mellitus type 2, IL-6 Interleukin-6, TNF- α Tumor necrosis factor-alfa, sCD14 Soluble CD14, DM2 Diabetes mellitus type 2